William D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
William D. Tap, MD
Advertisement
Articles by William D. Tap, MD
William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.
William D. Tap, MD, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).
Advertisement
Latest Updated Articles
The Potential to Combine KIT and CTLA-4 Blockade in Patients With GISTPublished: September 10th 2014 | Updated:
A Phase I Study of the CSF1R Kinase Inhibitor PLX3397 for PVNSPublished: June 2nd 2014 | Updated:
Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaPublished: November 7th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
